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Abstract
Objective
In the Prostate Cancer Prevention Trial (PCPT), finasteride reduced the risk of prostate can-
cer by 25%, even though high-grade prostate cancer was more common in the finasteride
group. However, it remains to be determined whether finasteride concentrations may affect
prostate cancer risk. In this study, we examined the association between serum finasteride
concentrations and the risk of prostate cancer in the treatment arm of the PCPT and deter-
mined factors involved in modifying drug concentrations.
Methods
Data for this nested case-control study are from the PCPT. Cases were drawn from men
with biopsy-proven prostate cancer and matched controls. Finasteride concentrations were
measured using a liquid chromatography-mass spectrometry validated assay. The associa-
tion of serum finasteride concentrations with prostate cancer risk was determined by logistic
regression. We also examine whether polymorphisms in the enzyme target and metabolism
genes of finasteride are related to drug concentrations using linear regression.
Results and Conclusions
Among men with detectable finasteride concentrations, there was no association between
finasteride concentrations and prostate cancer risk, low-grade or high-grade, when
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finasteride concentration was analyzed as a continuous variable or categorized by cutoff
points. Since there was no concentration-dependent effect on prostate cancer, any expo-
sure to finasteride intake may reduce prostate cancer risk. Of the twenty-seven SNPs as-
sessed in the enzyme target and metabolism pathway, five SNPs in two genes, CYP3A4
(rs2242480; rs4646437; rs4986910), and CYP3A5 (rs15524; rs776746) were significantly
associated with modifying finasteride concentrations. These results suggest that finasteride
exposure may reduce prostate cancer risk and finasteride concentrations are affected by
genetic variations in genes responsible for altering its metabolism pathway.
Trial Registration
ClinicalTrials.gov NCT00288106
Introduction
Prostate tissue growth and differentiation is dependent on androgen hormones and regulated
via the androgen receptor (AR) [1,2]. Testosterone is irreversibly converted to the more physi-
ologically potent androgen 5α-dihydrotestosterone (DHT) mediated by the androgen metabo-
lizing enzymes steroid 5a-reductase types I and II in the prostate tissue (encoded by the
SRD5A1 and SRD5A2 genes, respectively) [3] and also by steroid 5α-reductase type III (en-
coded by SRD5A2L or SRD5A3) recently identified in castration-resistant prostate cancer cells
[4,5].
Finasteride is a specific and potent SRD5A2 inhibitor [6,7,8], but it can also block the
SRD5A1 enzyme, although at a much slower rate [9] and SRD5A3 activity [10]. Several muta-
tions on the SRD5A genes have been reported that changed the expression level of 5α-reductase
[11,12]; thus genetic polymorphisms in these genes may affect enzyme activity and thus lead to
individual variability in drug efficacy. Finasteride is extensively metabolized in the liver, pri-
marily via the CYP3A subfamily, involving CYP3A4-mediated hydroxylation and oxidation re-
actions [13]. The CYP3A subfamily exhibits high sequence homology and various isoforms
(e.g., CYP3A4 and CYP3A5) share similar substrate specificity. In fact, CYP3A5 is reported to
be a major contributor to the metabolism of many CYP3A-mediated drugs and is highly poly-
morphic [14]. There is currently no published literature on the effects of CYP3A4 and CYP3A5
genetic variations and finasteride metabolism.
Treatment with finasteride results in a significant reduction of prostatic and circulating
DHT levels. Due to the role of DHT in the development of prostate cancer, it was hypothesized
that finasteride could be used effectively as a chemopreventive agent to reduce the risk of this
disease. In the Prostate Cancer Prevention Trial (PCPT), a randomized, placebo-controlled
trial testing whether finasteride could reduce the 7-year period prevalence of prostate cancer,
finasteride reduced the risk of prostate cancer by 25%, even though high-grade prostate cancer
was more common in the finasteride group [15].
Here, we investigate the association of serum finasteride concentrations with prostate cancer
risk using a nested case-control study in the finasteride-treated arm of the PCPT. We also ex-
amine whether polymorphisms in the enzyme target and metabolism genes of finasteride, such
as SRD5A2, CYP3A4, and CYP3A5, are related to drug concentrations. Findings from this
study could provide further insight into the role of finasteride for cancer prevention and the
etiology of the increased risk of high-grade cancer among men treated with finasteride, as well
as improve our understanding of the interindividual responses to finasteride treatment.
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Methods
Study Design, Study Population, and Data Collection
All data for this study are from the PCPT (SWOG-9217) [15,16]. Details of the study design
and participant characteristics have been described previously [15,16]. Briefly, 18,882 men age
55 years and older with a normal digital rectal exam (DRE), prostate specific antigen (PSA)
level of 3 ng/mL or below, and no history of prostate cancer or other clinically significant co-
morbid conditions that would have precluded successful completion of the study protocol,
were randomized to receive either finasteride (5 mg/day) or placebo daily for seven years. Dur-
ing the course of the PCPT, men underwent annual DRE and PSA measures and a prostate bi-
opsy was recommended for all men with an abnormal DRE or a finasteride-adjusted PSA
of> 4.0 ng/mL. At the conclusion of the trial, either a prostate cancer diagnosis or end-of-
study biopsy was available from 59.6% of the participants in the finasteride treatment arm, and
63% from the placebo arm. This level of ascertainment agreed well with the study design as-
sumption that 60% of men would have an endpoint assessed. All men signed informed consent
and study procedures were approved by the Institutional Review Boards of the participating
221 study sites [15,16].
This study reported here is part of a large nested case-control study designed to examine
multiple hypotheses about prostate cancer and risk. Cancer cases and controls in this report
were from the finasteride-treated study arm. Cases were men with biopsy-determined prostate
cancer identified either by a for-cause or end-of-study biopsy and who had DNA from white
blood cells or serum available. Controls were selected from men who completed the end-of-
study biopsy procedure, had no evidence of prostate cancer and had archived DNA samples.
Controls were frequency matched to cases on distributions of age (in 5-year age groups), and
positive family history for first degree relative with prostate cancer. Controls were oversampled
on race to include all eligible non-white subjects to maximize power for subgroup analyses. Fi-
nasteride concentrations were available from 749 cases and 758 controls. For this analysis, all
men who were non-compliant to study drug were removed. Non-compliance was defined in
two ways: 1) finasteride concentrations below the lowest detectable limit of 1 ng/mL (n = 228)
and 2) self-report of going off study drug at some point before the finasteride concentration
was assessed (additional n = 6). The final sample size for analyses is 597 cases and 676 controls.
Of these, 532 cases and 646 controls also had single nucleotide polymorphism (SNP) data avail-
able. Participants who were excluded due to lack of adequate DNA were comparable to partici-
pants with adequate DNA in terms of demographic characteristics such as age, BMI, race, and
family history (data not shown).
Details regarding age, race/ethnicity, family history, physical activity (type, frequency, dura-
tion, pace, and intensity), usual alcohol consumption and history of smoking were collected at
baseline using self-administered questionnaires. Clinic staff measured height and weight at
randomization, and body mass index (BMI) was calculated as weight (kg) divided by height2
(m). Tumors were graded centrally and categorized as low grade = Gleason< 7; high
grade = Gleason 7, retaining the definitions used in the original trial report.
Blood Collection and Genotyping
Non-fasting blood specimens were collected at screening and yearly thereafter. Venous blood
was drawn into collection tubes without anticoagulant and serum was centrifuged, aliquoted,
and stored at -70°C until analysis. DNA was extracted from white blood cells using Qiagen
M48 robot (Valencia, CA) at NCI Frederick and then shipped to the Roswell Park Cancer Insti-
tute Genomics Core Facility and the University of Texas Health Science Center at San Antonio
Finasteride-Related Gene Polymorphisms and Prostate Cancer
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for genotyping by polymerase chain reaction (PCR) amplification using the Sequenom, Taq-
man, or Illumina platform assays. Briefly, SNP genotypes were determined using the Illumina
VeraCode GoldenGate genotyping assay (Illumina Inc.; San Diego, CA). The list of SNPs were
submitted to Illumina and scored with the Assay Design Tool (ADT). Those SNPs with accept-
able scores were developed into an oligonucleotide pool assay (OPA) designed for a VeraCode
GoldenGate panel. Two hundred fifty nanograms of DNA were used as the template for the
assay. The assay was performed in 96 well plates following the established protocol (Illumina).
The plates were scanned using an Illumina BeadXpress reader and the genotypes were analyzed
using GenomeStudio software (Illumina). Interplate and intraplate replicates were included as
quality control measures. Twenty-seven SNPs in SRD5A2, SRD5A2L, CYP3A4, and CYP3A5
were genotyped. Primer sequences will be provided upon request.
Sample Collection and Measurement of Finasteride Serum
Concentrations
For most men (90%), samples used to determine finasteride concentrations were measured at 3
years post-baseline. For the other 10%, time points ranged from 1–7 years post-baseline. Steady
state finasteride concentrations were measured using a liquid chromatography-mass spectrom-
etry validated method on a HP 1100 system (Agilent Technology, Palo Alto, CA, USA) coupled
with a single-quadrupole mass spectrometric detector (Agilent 1100 MSD), as described previ-
ously [17], which was further modified and validated in serum. The lower limit of quantitation
for finasteride was established at 1 ng/mL. Laboratory personnel were blinded to the case-con-
trol status of all participants. Two sets of QC samples, 20 in each set, were included for quality
control, and the coefficients of variation were 6.5% and 7.4%.
Statistical Analysis
We compared baseline demographic and lifestyle characteristics of prostate cancer cases and
controls by student t test for continuous variables and chi-square test for categorical variables.
Serum concentrations of finasteride were categorized based on clinically defined cut points. Lo-
gistic regression was used to calculate ORs and 95% CIs for risk of total prostate cancer, and
polytomous logistic regression was used to calculate ORs and 95% CIs of both low-grade and
high-grade prostate cancers. The polytomous regression with a generalized logit link permits a
model including both low-grade and high-grade cancers as outcomes in the same model, con-
trasted with no cancer. Tests for linear trend for finasteride concentration were based on an or-
dinal variable corresponding to rank (lowest to highest). Model covariates were carefully
selected based on a priori information about potential confounding as well as diagnostic proce-
dures completed as part of our modeling exercises. Final covariates included age, race (white/
black/others), time of day of finasteride blood draw, and family history of prostate cancer. To
determine the association between single SNP and finasteride levels among whites, mean con-
centrations of finsteride were calculated for each allele, and p-values were calculated using line-
ar regression adjusted for age and alcohol consumption. All statistical tests were two-sided,
with P< 0.05 considered statistically significant. SAS (version 9.2) and R (version 2.15.1) were
used for all statistical analyses. Haploview v4.1 was used for assessing LD patterns and haplo-
type association statistics [18]. Haplotype blocks were determined using the algorithm of Ga-
briel et al [19].
Results
Demographic and lifestyle characteristics of the PCPT study population in the finasteride treat-
ment arm are listed in Table 1. Cases and controls did not differ with respect to age, BMI,
Finasteride-Related Gene Polymorphisms and Prostate Cancer
PLOS ONE | DOI:10.1371/journal.pone.0126672 May 8, 2015 4 / 13
physical activity, current smoking status or family history of prostate cancer. Because minori-
ties were oversampled (all eligible non-Caucasians were included) in the control group, there
were more blacks or other race (non-whites) in the control group. We examined the potential
predictors of finasteride concentrations and found that drug serum concentrations were signif-
icantly associated with age at baseline and alcohol consumption specifically more than 30 g/d
(Table 2). Mean finasteride concentrations were higher in older participants (p<0.0001) and in
individuals who consumed more than 30g/d of alcohol (p<0.02).
Table 1. Demographics and lifestyle characteristics of cases and controls of the Prostate Cancer Prevention Trial participants in the treatment
arm (n = 1273).
Control (n = 676) Case (n = 597) p-value
Mean (SD)
Age (y) 63.8 (5.6) 64.1 (5.8) NA*
BMI (kg/m2) 27.7 (4.1) 27.5 (3.8) 0.54
Waist circumference, cm 102.0 (11.1) 101.8 (10.3) 0.72
Waist:hip ratio 1.0 (0.1) 1.0 (0.1) 0.54
Alcohol intake, g/d 9.1 (13.9) 10.1 (15.1) 0.23
Smoking, pack-years 14.9 (16.8) 14.3 (16.2) 0.58
Finasteride concentrations, ng/mL 30.05 (19.72) 29.35 (19.35) 0.53
n (%)
Diabetes 49 (7.2) 30 (5.0) 0.10
Family history of prostate cancer 147 (21.7) 135 (22.6) NA*
Race NA*
White (Non-Hispanic) 503 (74.4) 556 (93.1)
Black 91 (13.5) 27 (4.5)
Other 82 (12.1) 14 (2.3)
BMI (kg/m2) 0.96
Normal (<25) 181 (27.0) 156 (26.4)
Overweight (25 to <30) 333 (49.6) 298 (50.3)
Obese (> = 30) 157 (23.4) 138 (23.3)
Physical Activity 0.52
Sedentary 130 (19.3) 117 (19.7)
Light 263 (39.1) 249 (41.8)
Moderate 213 (31.7) 183 (30.8)
Active 66 (9.8) 46 (7.7)
Alcohol Intake 0.71
Nondrinker 159 (23.5) 141 (23.6)
<30 g/d 459 (67.9) 397 (66.5)
> = 30 g/d 58 (8.6) 59 (9.9)
Smoking Status 0.21
Never Smoker 237 (35.1) 204 (34.2)
Current Smoker 57 (8.4) 36 (6.0)
Past Smoker 382 (56.5) 357 (59.8)
Education 0.02
High school or less 145 (21.5) 106 (17.8)
Some college 210 (31.1) 161 (27.0)
Graduate/professional school 320 (47.4) 330 (55.3)
* By study design, controls were frequency matched to cases based on age and family history, and oversampled to include all non-whites.
doi:10.1371/journal.pone.0126672.t001
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Table 3 gives the results for the associations of finasteride serum concentrations with pros-
tate cancer risk. Among individuals with detectable finasteride concentrations, there was no as-
sociation between finasteride concentrations and risk of overall (OR, 0.97; 95% CI, 0.91–1.04),
low-grade (OR, 0.96; 95% CI, 0.89–1.04), or high-grade (OR, 1.00; 95% CI, 0.93–1.09) prostate
cancer when finasteride concentration was analyzed as a continuous variable or categorized by
cutoff points. The results remain the same with high-grade disease classified as Gleason 8–10
(data not shown). Since the odds ratio for prostate cancer based on dose were comparable, we
can presume that on average all plasma concentrations have a 25% risk reduction of prostate
cancer as was reported in the primary treatment report [15]. Thus, while there was no concen-
tration-dependent effect on prostate cancer, we concluded that any exposure to finasteride in-
take may reduce prostate cancer risk. A sensitivity analysis was performed for cases diagnosed
by for-cause biopsy and the results were similar to Table 3 (data not shown). We found no
Table 2. Mean finasteride levels (ng/mL) stratified by categories of demographic measures among
treatment-compliant men in the Prostate Cancer Prevention Trial finasteride arm.
Characteristic N Mean (SD) p-value
Age * <0.0001
55–59 322 26.68 (16.58)
60–64 396 28.23 (18.64)
65–69 325 31.94 (21.06)
70+ 230 33.40 (21.74)
Diabetes ** 0.56
No 1194 29.64 (19.47)
Yes 79 30.96 (20.72)
Family History ** 0.40
No 991 29.97 (20.06)
Yes 282 28.85 (17.62)
Race ** 0.08
Non-hispanic White 1059 29.71 (19.46)
Black 118 27.05 (18.10)
Other 96 33.07 (21.75)
BMI * 0.16
Normal (BMI <25) 337 30.22 (21.47)
Overweight (BMI 25 to <30) 631 30.22 (19.45)
Obese (BMI > = 30) 295 27.95 (17.22)
Physical Activity * 0.76
Sedentary 247 29.85 (20.35)
Light 512 29.91 (19.98)
Moderate/Active 508 29.48 (18.68)
Alcohol Intake * 0.02
Non-drinker 300 28.76 (19.58)
>0 to <30 g/day Alcohol 856 29.34 (19.09)
> = 30 g/day Alcohol 117 34.96 (21.99)
Current Smoking Status ** 0.11
Current Non-Smoker 1180 29.48 (19.40)
Current Smoke 93 32.81 (21.12)
* p-value is based on a trend test
** p-value is based on an analysis of variance F-test
doi:10.1371/journal.pone.0126672.t002
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association between finasteride concentration-dependent effects and prostate cancer risk for
cases diagnosed by for-cause biopsy.
The association between finasteride concentrations and polymorphisms in enzyme target
and metabolism genes of finasteride are shown in Table 4. Of the twenty-seven SNPs assessed,
five SNPs in CYP3A4 (rs2242480; rs4646437; rs4986910) and CYP3A5 (rs776746; rs15524)
were associated with finasteride concentrations. For three of the SNPs, the variant allele was as-
sociated with higher finasteride concentrations (e.g. CYP3A4 rs4986910, Ptrend = 0.005;
CYP3A5 rs776746 and rs15524, Ptrend = 0.001 and Ptrend = 0.006, respectively). The variant al-
lele increased mean finasteride levels by>1.5-fold. The remaining two SNPs were associated
with lower finasteride concentrations (e.g. CYP3A4 rs2242480, Ptrend = 0.004; and rs4646437,
Ptrend = 0.002) and the homozygous variant alleles reduced mean finasteride levels by one half.
A sensitivity analysis for the SNP-finasteride association among controls only was performed
and showed statistical significance for only two gene variants, CYP3A4 rs4646437 (p = 0.04)
and CYP3A5 rs776746 (p = 0.03) (data not shown). These two variants were also statistically
significant when cases and controls were combined as shown in Table 4. We found no associa-
tions between finasteride concentrations and polymorphisms in enzyme targets of the SRD5A2
or SRD5A2L/SRD5A3 genes.
The pairwise linkage disequilibrium (LD) structure was constructed with all SNPs evaluated
for each gene. Since CYP3A4 and CYP3A5 are located adjacent to each other on chromosome
7, the SNPs in each gene were evaluated together, which revealed one LD block consisting of 2
CYP3A4 variants (rs2242480 and rs4646437) (Fig 1A). A strong LD was observed between
these two variants with haplotype frequencies of C/C 0.908, C/T 0.076, C/T 0.015. These two
variants were also found to be associated with finasteride concentrations. For SRD5A2, two LD
blocks were identified, with rs6760199 and rs6732223 in the same LD block (block 1) while
rs4952197 and rs2300700 were in block 2 exhibiting high LD with corresponding haplotype
frequencies shown in Fig 1B. For SRD5A3, two LD blocks were also identified with high LD
(block 1: rs10001607 and rs11133373; block 2: rs7663650 and rs819270) as shown in Fig 1C.
Discussion
The PCPT demonstrated that finasteride reduced the risk of prostate cancer by about 25%
[15]. Based on these findings, we investigated whether finasteride concentrations may affect
prostate cancer risk. In this nested case-control study from the PCPT, when we examined only
individuals with detectable finasteride levels, we found no difference between any drug serum
Table 3. Associations of finasteride concentrations with prostate cancer risk in PCPT, overall and stratified by cancer grade.
All Cancer (Low) Gleason 2–6 (High) Gleason 7–10
Finasteride Concentrations N control N case OR (95% CI) N case OR (95% CI) N case OR (95% CI)
1 to <10 ng/mL 91 87 ref 51 ref 31 ref
10 to <20 ng/mL 154 123 0.76 (0.51–1.12) 73 0.78 (0.49–1.23) 44 0.74 (0.43–1.28)
20 to <30 ng/mL 128 136 1.09 (0.73–1.62) 81 1.13 (0.72–1.79) 51 1.11 (0.65–1.89)
30 to <40 ng/mL 123 99 0.74 (0.49–1.12) 60 0.78 (0.48–1.26) 35 0.72 (0.41–1.28)
40 to <50 ng/mL 84 72 0.81 (0.52–1.28) 32 0.63 (0.36–1.11) 36 1.13 (0.63–2.03)
50+ 95 76 0.82 (0.52–1.29) 41 0.79 (0.46–1.34) 32 0.95 (0.52–1.73)
p-trend 0.42 0.22 0.73
Continuous, per 10ng/mL 675 593 0.97 (0.91–1.04) 338 0.96 (0.89–1.04) 229 1.00 (0.93–1.09)
Odds ratios are adjusted for age, race (white vs black vs others), time of day of blood draw, and family history of prostate cancer.
doi:10.1371/journal.pone.0126672.t003
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Table 4. Association between finasteride concentrations and genes in metabolism and target pathways among white men. #
Gene SNP Genotype N % Frequency Finasteride (ng/mL) p-trend *
Mean (SD)
CYP3A4 rs2242480 CC 823 85.6 30.30 (19.53) 0.004
CT 130 13.5 26.21 (17.09)
TT 8 0.8 15.07 (8.00)
rs2740574 AA 912 93.7 29.90 (19.51) 0.060
AG 59 6.1 26.45 (14.65)
GG 2 0.2 13.62 (15.81)
rs4646437 CC 801 83.3 30.35 (19.69) 0.002
CT 149 15.5 26.48 (17.18)
TT 12 1.2 16.85 (7.46)
rs4986907 GG 973 100.0 29.62 (19.24) NA
rs4986910 AA 953 98.6 29.46 (19.21) 0.005
(M445T) AG 14 1.4 43.28 (20.30)
CYP3A5 rs15524 CC 6 0.6 17.17 (8.70) 0.006
CT 121 12.5 25.73 (14.01)
TT 842 86.9 30.26 (19.90)
rs28365085 TT 723 100.0 30.04 (19.27) NA
rs776746 AA 5 0.5 17.21 (9.72) 0.001
AG 111 11.7 24.58 (14.12)
GG 832 87.8 30.34 (19.82)
SRD5A2 rs11675297 AA 3 0.3 49.30 (11.95) 0.866
AG 60 6.3 28.81 (22.57)
GG 888 93.4 29.61 (19.07)
rs2300700 AA 205 21.5 28.35 (18.27) 0.083
AG 477 50.1 29.16 (19.92)
GG 271 28.4 31.70 (18.90)
rs4952197 AA 78 8.1 31.93 (17.42) 0.850
AG 369 38.3 28.58 (18.31)
GG 517 53.6 30.06 (20.18)
rs523349 CC 394 41.8 30.16 (20.18) 0.790
(V89L) CG 466 49.5 28.85 (18.99)
GG 82 8.7 30.88 (17.17)
rs6732223 CC 240 26.0 32.16 (19.11) 0.104
CT 468 50.8 28.28 (18.47)
TT 214 23.2 28.97 (19.15)
rs6760199 AA 77 8.0 32.56 (17.39) 0.920
AC 380 39.3 28.75 (18.27)
CC 511 52.8 29.88 (20.19)
rs9282858 AG 64 8.9 28.09 (18.83) 0.630
(A49T) GG 659 91.1 30.27 (19.47)
rs9332975 AA 778 80.3 29.10 (19.35) 0.120
AG 181 18.7 31.52 (18.82)
GG 10 1.0 33.19 (22.28)
Gene SNP Genotype N % Frequency Finasteride (ng/mL) p-trend *
Mean (SD)
SRD5A2L rs10001607 CC 292 30.6 29.15 (20.13) 0.950
(SRD5A3) CT 466 48.8 30.00 (18.40)
(Continued)
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Table 4. (Continued)
Gene SNP Genotype N % Frequency Finasteride (ng/mL) p-trend *
Mean (SD)
TT 196 20.5 28.99 (18.67)
rs11133373 CC 449 46.4 29.62 (17.68) 1.000
CG 433 44.7 29.73 (20.42)
GG 86 8.9 29.51 (21.41)
rs7663650 CC 400 41.3 30.23 (18.88) 0.480
CT 465 48.0 28.98 (19.49)
TT 103 10.6 29.59 (19.98)
rs7682870 AA 588 60.9 29.72 (19.66) 0.890
AC 336 34.8 29.07 (18.82)
CC 41 4.2 31.67 (16.25)
rs819270 AA 92 9.6 32.84 (22.29) 0.120
AG 388 40.3 29.77 (18.17)
GG 483 50.2 28.81 (19.47)
# Treatment compliant men in the PCPT finasteride arm.
doi:10.1371/journal.pone.0126672.t004
Fig 1. Linkage disequilibrium (LD) pattern and haplotype architecture for (A)CYP3A4& CYP3A5; (B) SRD5A2; and (C) SRD5A2L/SRD5A3 genes.
The haplotype block structure, as exhibited by Haploview is shown. LD was measured using data from all white subjects in the present study. The haplotype
blocks were determined using the criteria described by Gabriel et al. The physical position of each SNP is presented in the upper diagram. Each diamond
contains the level of LD measured by Hedrick's multiallelic D0 between pairs of single nucleotide polymorphisms. Shading shows the magnitude and
significance of pairwise LD, with darker shades representing stronger LD; the diamond without a number corresponds to D0 = 1. Haplotypes for the variations
and their population frequency (light gray color) are shown below each haplotype block of the corresponding genes. The SNP numbers across the top of the
haplotypes correspond to those in the Haploview plot. D0 indicates the level of recombination between two blocks and is shown in the crossing area. The
connection from one block to the next block is displayed through frequency corresponding to the thickness of the line.
doi:10.1371/journal.pone.0126672.g001
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concentrations and the risk of overall, low- or high-grade prostate cancer. This suggests that
since there was no concentration-dependent effect on prostate cancer, any exposure to finaste-
ride intake may reduce prostate cancer risk. The observed effect could be attributed to partici-
pant adherence to therapy resulting in detectable drug levels, inter-individual variation in drug
metabolism resulting in increased drug concentrations, or random variability from post-
hoc analysis.
Moreover, we investigated the potential predictors of finasteride concentrations and found
that drug serum concentrations were significantly associated with age at baseline and alcohol
consumption specifically more than 30 g/d. Mean finasteride concentrations were higher in
older participants, suggesting that perhaps the liver function (where finasteride is primarily
metabolized) and metabolism of the older participants were more impaired compared to youn-
ger participants. We also found that men who consumed more than 30g/d of alcohol appeared
to have higher drug concentrations. Results from a previous case-control study of the PCPT
population demonstrated that heavy drinking (50g of alcohol consumption) made finasteride
ineffective for reducing prostate cancer risk [20]. Whether alcohol consumption positively or
negatively affects liver function and subsequent finasteride metabolism remains to be elucidat-
ed. Nonetheless, variability in the concentration may also be due to the time of day of blood
draw as finasteride concentrations were lower for men who had their blood drawn later in the
day (data not shown).
We next investigated whether polymorphisms in the enzyme target and metabolism genes
of finasteride may in fact alter drug levels. Finasteride is a specific and potent steroid 5α-reduc-
tase type II inhibitor. Previous studies have demonstrated significant pharmacogenetic varia-
tion for finasteride at the SRD5A2 locus where specific mutations (rs523349; rs9282858) affect
enzyme stability or substrate binding by finasteride [11,12]. Our current genotyping study
found no associations between finasteride concentrations and polymorphisms in enzyme tar-
gets of the SRD5A2 or SRD5A2L/SRD5A3 genes.
Genetic variants in the CYP3A4 and CYP3A5 genes involved in finasteride metabolism were
significantly associated with serum concentrations in our study. The homozygous minor allele
of CYP3A4 rs2242480 and rs4646437 were associated with lower finasteride levels.
SNP rs2242480 (CYP3A41G) resides within intron 10 and reporter gene assays indicated
that the minor allele has a significantly higher transcriptional activity [21]. Previous studies
have demonstrated its association with lipid-lowering efficacy of atorvastatin [22] or tacroli-
mus pharmacokinetics in renal transplant patients [23]. SNP rs4646437 lies within intron 7 of
CYP3A4 and although the functional role of this SNP remains to be determined, it has been as-
sociated with CYP3A4 protein expression and enzyme activity in human liver microsomes ob-
served in men only [24]. The variant allele in 3 SNPs (e.g. CYP3A4 rs4986910; CYP3A5
rs776746 and rs15524) were associated with higher finasteride concentrations. The minor allele
of CYP3A4 rs4986910 (CYP3A43), located in exon 12, significantly increased mean finasteride
levels by more than 1.5-fold. While the allele frequency for this variant is low, studies have
shown that the SNP was associated with reduced enzyme function, which may explain the
higher finasteride levels observed [25]. SNP rs776746 (CYP3A53), located in intron 3
(6986A>G), produced a cryptic splice site and premature termination of the protein, resulting
in loss of CYP3A5 expression and subsequently affecting protein production and enzyme activ-
ity [14]. The wild type allele (CYP3A51) occurs at a lower frequency than the variant allele
(CYP3A53). Homozygous carriers of the CYP3A53 variant allele produce very low or unde-
tectable levels of functional CYP3A5 protein. On the contrary, heterozygous or homozygous
carriers for CYP3A51 would display higher clearance and lower oral bioavailability of drugs,
resulting in a lack of efficacy from a standard dose. Indeed, the homozygous AA genotype in
rs776746 has been associated with poor response to imatinib therapy [26] and with decreased
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sunitinib response and tolerability [27]. Similar to finasteride, the rs776746 SNP has been asso-
ciation with serum tacrolimus concentration where carriers of a G/G genotype exhibited higher
drug levels than the A allele (GA or AA) [28]. Moreover, higher mean finasteride concentra-
tions have been found among carriers of the homozygous variant (T/T genotype) of CYP3A5
rs15524 (CYP3A51D), which was similar to that observed for cyclosporine [28].
There are strengths and limitations to our study. The PCPT was a large placebo-controlled
randomized trial that specified prostate cancer outcomes would be based on biopsy results. As
such, the control group used in these analyses all had negative prostate biopsies, largely elimi-
nating the possibility that controls may have had undiagnosed or undetected disease. Addition-
ally, data were carefully collected throughout the course of the trial with a central pathology
laboratory for uniform adjudication of all cases (including adjudication of Gleason grade) and
we used a highly sensitive and specific assay for quantitating finasteride serum concentrations.
However, our study was limited in that the PCPT included few minorities. Although we over-
sampled non-white controls to increase power for analyses by race, the power for any race-spe-
cific subgroups was hampered. Another limitation was that the finasteride concentrations were
drawn from a very specific time-point, and hence don't provide any information about dura-
tion of use or long-term compliance on drug therapy. Given the drug’s short half-life, the low
or undetectable levels of finasteride may have resulted from random missed dose(s) prior to
sampling time or noncompliance. However, our analysis has shown that individuals with finas-
teride concentrations greater than 1 ng/mL correlated with their self-reported compliance of
taking the drug therapy (data not shown). Finally, serum concentrations may not be represen-
tative of tissue levels.
Conclusions
In summary, this study demonstrates the association between finasteride exposure and prostate
cancer risk. Among treatment compliant men, there was no concentration-response effect of fi-
nasteride on disease risk. This is also the first study to show an association between finasteride
concentrations and genetic variations in genes responsible for altering its metabolism pathway.
We identified variants that influenced finasteride concentrations, which may explain the inter-
individual variation observed in drug level differences. Our study has paved the way for future
studies to conduct pharmacogenetic analyses of functional SNPs in finasteride-related metabo-
lism genes that will likely contribute to an individual’s response to
finasteride chemoprevention.
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